Literature DB >> 26370602

Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids.

E Appiah-Kusi1, E Leyden1, S Parmar1, V Mondelli2, P McGuire1, S Bhattacharyya1.   

Abstract

The aim of this article is to summarize current evidence regarding alterations in the neuroendocrine stress response system and endocannabinoid system and their relationship in psychotic disorders such as schizophrenia. Exposure to stress is linked to the development of a number of psychiatric disorders including psychosis. However, the precise role of stress in the development of psychosis and the possible mechanisms that might underlie this are not well understood. Recently the cannabinoid hypothesis of schizophrenia has emerged as a potential line of enquiry. Endocannabinoid levels are increased in patients with psychosis compared with healthy volunteers; furthermore, they increase in response to stress, which suggests another potential mechanism for how stress might be a causal factor in the development of psychosis. However, research regarding the links between stress and the endocannabinoid system is in its infancy. Evidence summarized here points to an alteration in the baseline tone and reactivity of the hypothalamic-pituitary-adrenal (HPA) axis as well as in various components of the endocannabinoid system in patients with psychosis. Moreover, the precise nature of the inter-relationship between these two systems is unclear in man, especially their biological relevance in the context of psychosis. Future studies need to simultaneously investigate HPA axis and endocannabinoid alterations both at baseline and following experimental perturbation in healthy individuals and those with psychosis to understand how they interact with each other in health and disease and obtain mechanistic insight as to their relevance to the pathophysiology of schizophrenia.

Entities:  

Keywords:  Cannabis; endocannabinoid system; hypothalamic–pituitary–adrenal axis; psychosis; schizophrenia; stress

Mesh:

Substances:

Year:  2015        PMID: 26370602     DOI: 10.1017/S0033291715001786

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  12 in total

1.  The relationship between cannabis use and cortisol levels in youth at ultra high-risk for psychosis.

Authors:  Emily E Carol; Robert L Spencer; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2017-05-30       Impact factor: 4.905

2.  Investigating Associations Between Depressive Symptoms and Anti-/Pro-Inflammatory Nutrients in an Elderly Population in Northern China: A Bayesian Kernel Machine Regression Approach.

Authors:  Ruiqiang Li; Wenqiang Zhan; Xin Huang; Limin Zhang; Yan Sun; Zechen Zhang; Wei Bao; Yuxia Ma
Journal:  J Inflamm Res       Date:  2021-10-09

Review 3.  The effects of cannabis use on salience attribution: a systematic review.

Authors:  Surapi Bhairavi Wijayendran; Aisling O'Neill; Sagnik Bhattacharyya
Journal:  Acta Neuropsychiatr       Date:  2016-11-21       Impact factor: 3.403

4.  Diet-Related Inflammation is Associated with Major Depressive Disorder in Bahraini Adults: Results of a Case-Control Study Using the Dietary Inflammatory Index.

Authors:  Wen Chen; Mo'ez Al-Islam E Faris; Nicola Luigi Bragazzi; Haifa M S AlGahtani; Zahra Saif; Ahmed Jahrami; Nitin Shivappa; James R Hebert; Haitham Jahrami
Journal:  J Inflamm Res       Date:  2021-04-15

5.  Cannabidiol modulation of hippocampal glutamate in early psychosis.

Authors:  Aisling O'Neill; Luciano Annibale; Grace Blest-Hopley; Robin Wilson; Vincent Giampietro; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2021-04-16       Impact factor: 4.153

Review 6.  Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.

Authors:  Marco Colizzi; Sagnik Bhattacharyya
Journal:  Curr Addict Rep       Date:  2017-04-29

7.  Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.

Authors:  Musa Basseer Sami; Sagnik Bhattacharyya
Journal:  J Psychopharmacol       Date:  2018-03-29       Impact factor: 4.153

8.  Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans.

Authors:  Marco Colizzi; Nathalie Weltens; Philip McGuire; Lukas Van Oudenhove; Sagnik Bhattacharyya
Journal:  Brain Sci       Date:  2019-04-25

9.  Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.

Authors:  Sagnik Bhattacharyya; Robin Wilson; Elizabeth Appiah-Kusi; Aisling O'Neill; Michael Brammer; Jesus Perez; Robin Murray; Paul Allen; Matthijs G Bossong; Philip McGuire
Journal:  JAMA Psychiatry       Date:  2018-11-01       Impact factor: 21.596

10.  Pituitary volume reduction in schizophrenia following cognitive behavioural therapy.

Authors:  Preethi Premkumar; Danielle Bream; Adegboyega Sapara; Dominic Fannon; Anantha P Anilkumar; Elizabeth Kuipers; Veena Kumari
Journal:  Schizophr Res       Date:  2017-04-21       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.